{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:45:41Z","timestamp":1793159141795,"version":"4.5.0"},"reference-count":207,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e34927","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T11:59:17Z","timestamp":1721476757000},"page":"e34927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview"],"prefix":"10.1016","volume":"10","author":[{"given":"Ruth","family":"Henr\u00edquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9467-5097","authenticated-orcid":false,"given":"Isabel","family":"Mu\u00f1oz-Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e34927_bib1","first-page":"340","article-title":"Accelerating next-generation vaccine development for global disease prevention","author":"Koff","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e34927_bib2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1402981111","article-title":"Vaccines, new opportunities for a new society","volume":"111","author":"Rappuoli","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/0196-6553(82)90003-7","article-title":"The global eradication of smallpox","volume":"10","author":"Strassburg","year":"1982","journal-title":"AJIC Am. J. Infect. Control"},{"key":"10.1016\/j.heliyon.2024.e34927_bib4","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168113","article-title":"Historical advances in structural and molecular biology and how they impacted vaccine development","volume":"435","author":"Koff","year":"2023","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib6","first-page":"429","volume":"3","author":"Loomis","year":"2015"},{"key":"10.1016\/j.heliyon.2024.e34927_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00578-15","article-title":"High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination","volume":"89","author":"Sijmons","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2015.4","article-title":"Epstein\u2013barr virus vaccines","volume":"4","author":"Cohen","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib10","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2021.1960162","article-title":"Current vaccine approaches and emerging strategies against herpes simplex virus (HSV)","volume":"20","author":"Wijesinghe","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: the first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and multipathogen viral vector vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/imr.12478","article-title":"Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention","volume":"275","author":"Brady","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2024.e34927_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines6030035","article-title":"Neutralizing anti-hemagglutinin monoclonal antibodies induced by gene-based transfer have prophylactic and therapeutic effects on influenza virus infection","volume":"6","author":"Yamazaki","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib15","author":"Yang"},{"key":"10.1016\/j.heliyon.2024.e34927_bib16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-022-00503-y","article-title":"The use of viral vectors in vaccine development","volume":"7","author":"Travieso","year":"2022","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines8040680","article-title":"Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats","volume":"8","author":"Vrba","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1128\/JVI.02184-14","article-title":"Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines","volume":"89","author":"Crosby","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib20","first-page":"163","article-title":"Single-cycle adenovirus vectors in the current vaccine landscape","volume":"17","author":"Barry","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib21","doi-asserted-by":"crossref","first-page":"13231","DOI":"10.1128\/JVI.79.21.13231-13238.2005","article-title":"A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector","volume":"79","author":"Publicover","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib24","first-page":"624","volume":"2","author":"Ura","year":"2014"},{"key":"10.1016\/j.heliyon.2024.e34927_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102210","article-title":"Viral vector vaccines","volume":"77","author":"McCann","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib57","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib58","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2004.15.1157","article-title":"The innate immune response to adenovirus vectors","volume":"15","author":"Muruve","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib59","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.77.19.10366-10375.2003","article-title":"Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Ad dl 1520) for treatment of liver tumors","volume":"77","author":"Hong","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib60","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.bioeng.10.061807.160514","article-title":"Molecular engineering of viral gene delivery vehicles","volume":"10","author":"Schaffer","year":"2008","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.heliyon.2024.e34927_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9101187","article-title":"Self-replicating rna viruses for vaccine development against infectious diseases and cancer","volume":"9","author":"Lundstrom","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib69","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","article-title":"Clinical use of lentiviral vectors","volume":"32","author":"Milone","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e34927_bib72","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-065X.2010.00967.x","article-title":"Immunization delivered by lentiviral vectors for cancer and infectious diseases","volume":"239","author":"Hu","year":"2011","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.heliyon.2024.e34927_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15030846","article-title":"Lentiviral vectors as a vaccine platform against infectious diseases","volume":"15","author":"Nemirov","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.heliyon.2024.e34927_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/v15112255","article-title":"Integrase defective lentiviral vector promoter impacts transgene expression in target cells and magnitude of vector-induced immune responses","volume":"15","author":"Mahesh","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/bit.26461","article-title":"Advancements in the design and scalable production of viral gene transfer vectors","volume":"115","author":"Sharon","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.heliyon.2024.e34927_bib87","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.heliyon.2024.e34927_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e34927_bib89","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib103","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.coviro.2020.09.003","article-title":"Rhabdoviruses as vectors for vaccines and therapeutics","volume":"44","author":"Scher","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib104","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.97.7.3544","article-title":"Recombinant rabies virus as potential live-viral vaccines for HIV-1","volume":"97","author":"Schnell","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/v8070183","article-title":"Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines","volume":"8","author":"Kim","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103132","article-title":"Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate","volume":"62","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101430","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib137","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","article-title":"Virus-like particle vaccines: immunology and formulation for clinical translation","volume":"17","author":"Donaldson","year":"2018","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib140","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib141","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8010139","article-title":"Recent progress on the versatility of virus-like particles","volume":"8","author":"Qian","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2018.02.002","article-title":"Recent advances in viral vectors in veterinary vaccinology","volume":"29","author":"Baron","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13567-022-01118-w","article-title":"Current situation and future direction of Newcastle disease vaccines","volume":"53","author":"Hu","year":"2022","journal-title":"Vet. Res."},{"key":"10.1016\/j.heliyon.2024.e34927_bib28","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1128\/JVI.00031-15","article-title":"Newcastle disease virus-vectored H7 and H5 live vaccines protect chickens from challenge with H7N9 or H5N1 avian influenza viruses","volume":"89","author":"Liu","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/311067a0","article-title":"Live recombinant vaccinia virus protects chimpanzees against hepatitis B","volume":"311","author":"Moss","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34927_bib30","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/378356","article-title":"Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen","volume":"188","author":"Monath","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib31","article-title":"Japanese encephalitis: risk of emergence in the United States and the resulting impact","volume":"16","author":"Monath","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib32","doi-asserted-by":"crossref","first-page":"7993","DOI":"10.1016\/j.vaccine.2010.09.035","article-title":"Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: randomised controlled phase 3 trials","volume":"28","author":"Torresi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14760584.2016.1123097","article-title":"Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV\u00ae) in children","volume":"15","author":"Chokephaibulkit","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib34","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1016\/j.vaccine.2019.08.018","article-title":"Clinical trials with GMO-containing vaccines in Europe: status and regulatory framework","volume":"37","author":"Kauffmann","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib113","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","article-title":"A vaccine against Ebola virus","volume":"181","author":"Ollmann Saphire","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34927_bib114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2021.03.008","article-title":"Ebola virus disease: current vaccine solutions","volume":"71","author":"Tomori","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib171","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01627-23","article-title":"Translational success of fundamental virology: a VSV-vectored Ebola vaccine","volume":"98","author":"Anderson","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e34927_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2019-029617","article-title":"Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review","volume":"9","author":"Mathebula","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.heliyon.2024.e34927_bib172","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa586","article-title":"Safety and immunogenicity of heterologous and homologous 2-dose regimens of adenovirus serotype 26- and modified vaccinia ankara-vectored Ebola vaccines: a randomized, controlled phase 1 study","volume":"226","author":"Goldstein","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib52","first-page":"1438","volume":"377","author":"Kennedy","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e34927_bib174","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","article-title":"Immunogenicity, lot consistency, and extended safety of rVSV\u0394G-ZEBOV-GP vaccine: a phase 3 randomized, double-blind, placebo-controlled study in healthy adults","volume":"220","author":"Halperin","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib139","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12275-017-7058-3","article-title":"Exploiting virus-like particles as innovative vaccines against emerging viral infections","volume":"55","author":"Jeong","year":"2017","journal-title":"J. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/298347a0","article-title":"Synthesis and assembly of hepatitis B virus surface antigen particles in yeast","volume":"298","author":"Valenzuela","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34927_bib150","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.tibtech.2013.09.002","article-title":"Virus-like particle-based human vaccines: quality assessment based on structural and functional properties","volume":"31","author":"Zhao","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib151","article-title":"Recombinant hepatitis B vaccine (Engerix-B\u00ae): a review of its immunogenicity and protective efficacy against hepatitis B","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e34927_bib158","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1177\/10600280221114469","article-title":"PreHevbrio: a new 3-antigen hepatitis B vaccine for adults","volume":"57","author":"Sucher","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e34927_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2014.05.064","article-title":"Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin","volume":"32","author":"Zhang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib152","article-title":"GARDASIL 9 (Human papillomavirus 9-valent vaccine, recombinant)","volume":"14","author":"Gupta","year":"2016","journal-title":"Skinmed"},{"key":"10.1016\/j.heliyon.2024.e34927_bib159","doi-asserted-by":"crossref","DOI":"10.4161\/hv.6.5.11023","article-title":"Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in CervarixTM, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine","volume":"6","author":"Deschuyteneer","year":"2010","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib169","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eclinm.2022.101789","article-title":"Optimal allocation strategies for HPV vaccination introduction and expansion in China accommodated to different supply and dose schedule scenarios: a modelling study","volume":"56","author":"You","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib153","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/21645515.2019.1669415","article-title":"RTS,S\/AS01 vaccine (MosquirixTM): an overview","volume":"16","author":"Laurens","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e34927_bib154","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/bit.28181","article-title":"Production of a high purity, C-tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions","author":"Mukhopadhyay","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.heliyon.2024.e34927_bib155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12936-024-04846-w","article-title":"A perspective on Oxford's R21\/Matrix-MTM malaria vaccine and the future of global eradication efforts","volume":"23","author":"Aderinto","year":"2024","journal-title":"Malar. J."},{"key":"10.1016\/j.heliyon.2024.e34927_bib193","first-page":"1","article-title":"Recent advances in lentiviral vaccines for HIV-1 infection","volume":"7","author":"Norton","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib43","author":"Custers"},{"key":"10.1016\/j.heliyon.2024.e34927_bib192","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/v16030368","article-title":"Exploring HIV vaccine progress in the pre-clinical and clinical setting: from history to future prospects","volume":"16","author":"Kaur","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.clinthera.2020.01.009","article-title":"Innovations in HIV-1 vaccine design","volume":"42","author":"Jones","year":"2020","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.heliyon.2024.e34927_bib190","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.coviro.2016.02.010","article-title":"Approaches to preventative and therapeutic HIV vaccines","volume":"17","author":"Gray","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib194","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e34927_bib195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1004360","article-title":"Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): a phase 1\/2a randomized trial","volume":"21","author":"Moodie","year":"2024","journal-title":"PLoS Med."},{"key":"10.1016\/j.heliyon.2024.e34927_bib181","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S1473-3099(15)00266-2","article-title":"High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial","volume":"15","author":"Liebowitz","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib182","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1473-3099(19)30584-5","article-title":"Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study","volume":"20","author":"Liebowitz","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib179","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1080\/21645515.2016.1210729","article-title":"Viral vector-based influenza vaccines","volume":"12","author":"de Vries","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e34927_bib183","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza a vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v12091033","article-title":"Progress in the development of universal influenza vaccines","volume":"12","author":"Sun","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib148","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/j.vaccine.2021.01.004","article-title":"Phase III: randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18\u201349 years of age","volume":"39","author":"Ward","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib197","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-020-00243-x","article-title":"Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses","volume":"5","author":"Bos","year":"2020","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib198","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e34927_bib199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2002083","article-title":"A comprehensive review of SARS-CoV-2 vaccines: pfizer, moderna & Johnson & Johnson","volume":"18","author":"Patel","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e34927_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e34927_bib55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e34927_bib201","doi-asserted-by":"crossref","DOI":"10.3390\/v13020317","article-title":"Viral vectors for COVID-19 vaccine development","volume":"13","author":"Lundstrom","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e34927_bib161","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109650","article-title":"A perspective on SARS-CoV-2 virus-like particles vaccines","volume":"115","author":"Gao","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2024.e34927_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fpls.2023.1170815","article-title":"Plant-made vaccines against viral diseases in humans and farm animals","volume":"14","author":"Su","year":"2023","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.heliyon.2024.e34927_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.101084","article-title":"GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial","volume":"4","author":"Capone","year":"2023","journal-title":"Cell Reports Med"},{"key":"10.1016\/j.heliyon.2024.e34927_bib204","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.729837","article-title":"Dual-antigen COVID-19 vaccine subcutaneous prime delivery with oral boosts protects NHP against SARS-CoV-2 challenge","volume":"12","author":"Gabitzsch","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib126","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo2847","article-title":"An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination","volume":"15","author":"Carre\u00f1o","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e34927_bib127","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00662-6","article-title":"Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico","volume":"8","author":"Ponce-de-Le\u00f3n","year":"2023","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib205","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/14760584.2024.2320861","article-title":"Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine","volume":"23","author":"Luvira","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib35","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.heliyon.2024.e34927_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis"},{"key":"10.1016\/j.heliyon.2024.e34927_bib37","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e34927_bib38","series-title":"Fields Virol","first-page":"1704","article-title":"Adenoviridae","author":"Berk","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e34927_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2012.04.005","article-title":"Adenovirus receptors: implications for targeting of viral vectors","volume":"33","author":"Arnberg","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e34927_bib40","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy411","article-title":"A replicating single-cycle adenovirus vaccine against Ebola virus","volume":"218","author":"Anguiano-Zarate","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/infdis\/jis670","article-title":"First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)","volume":"207","author":"Baden","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib46","doi-asserted-by":"crossref","DOI":"10.2217\/fvl-2016-0070","article-title":"Simian adenoviruses as vaccine vectors","volume":"11","author":"Morris","year":"2016","journal-title":"Future Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.607333","article-title":"Adenoviral vectors as vaccines for emerging avian influenza viruses","volume":"11","author":"Kerstetter","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000001224","article-title":"Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140","volume":"30","author":"Emmer","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.heliyon.2024.e34927_bib49","article-title":"A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection","volume":"10","author":"Hartnell","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101470","article-title":"HIV vaccinology: 2021 update","volume":"51","author":"Lee","year":"2021","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib51","article-title":"Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial","volume":"20","author":"Tapia","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e34927_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of Chad63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","author":"Hodgson","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib61","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.91.19.8802","article-title":"An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3","volume":"91","author":"Bett","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4110\/in.2021.21.e6","article-title":"Adenovirus vectors: excellent tools for vaccine development","volume":"21","author":"Chang","year":"2021","journal-title":"Immune Netw"},{"key":"10.1016\/j.heliyon.2024.e34927_bib63","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0065-3527(00)55014-3","article-title":"Adenovirus vectors for human gene therapy","volume":"55","author":"Hitt","year":"2000","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.heliyon.2024.e34927_bib64","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.93.12.5731","article-title":"A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and \u03b2-galactosidase","volume":"93","author":"Kochanek","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0005059","article-title":"Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines","volume":"4","author":"Weaver","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e34927_bib66","first-page":"462","article-title":"IIIa deleted adenovirus as a single-cycle genome replicating vector","author":"Crosby","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.heliyon.2024.e34927_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10030436","article-title":"Utilization of viral vector vaccines in preparing for future pandemics","volume":"10","author":"Hofmeyer","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib68","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm8563","article-title":"Comparison of replicating and nonreplicating vaccines against SARS-CoV-2","volume":"8","author":"Mudrick","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.heliyon.2024.e34927_bib70","series-title":"Fields Virol","first-page":"1424","article-title":"Retroviridae","author":"Goff","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e34927_bib71","series-title":"Fields Virol","first-page":"1502","article-title":"Human immunodeficiency viruses: replication","author":"Freed","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e34927_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-018-0448-8","article-title":"The role of integration and clonal expansion in HIV infection: live long and prosper Ben Berkhout, Alexander Pasternak","volume":"15","author":"Anderson","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.heliyon.2024.e34927_bib76","first-page":"272","article-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.heliyon.2024.e34927_bib77","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI200317098","article-title":"In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses","volume":"111","author":"Esslinger","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e34927_bib78","first-page":"439","article-title":"Lentivirus as a potent and mechanistically distinct vector for genetic immunization","volume":"9","author":"He","year":"2007","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"10.1016\/j.heliyon.2024.e34927_bib79","doi-asserted-by":"crossref","first-page":"8150","DOI":"10.1128\/JVI.72.10.8150-8157.1998","article-title":"Development of a self-inactivating lentivirus vector","volume":"72","author":"Miyoshi","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v13020355","article-title":"Integrase-defective lentiviral vector is an efficient vaccine platform for cancer immunotherapy","volume":"13","author":"Morante","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00171","article-title":"Integrase defective lentiviral vector as a vaccine platform for delivering influenza antigens","volume":"9","author":"Gallinaro","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.837","article-title":"A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity againts West Nile virus","volume":"8","author":"Iglesias","year":"2006","journal-title":"J. Gene Med."},{"key":"10.1016\/j.heliyon.2024.e34927_bib83","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0911742106","article-title":"HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells","volume":"106","author":"Dai","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2019.03.008","article-title":"Lentiviral vector-based dendritic cell vaccine suppresses HIV replication in humanized mice","volume":"27","author":"Norton","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.12.010","article-title":"Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models","volume":"29","author":"Ku","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2024.e34927_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00005","article-title":"AAV vectors vaccines against infectious diseases","volume":"5","author":"Nieto","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib91","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.chom.2021.08.002","article-title":"An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates","volume":"29","author":"Zabaleta","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2024.e34927_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.802147","article-title":"Development of an adeno-associated virus-vectored SARS-CoV-2 vaccine and its immunogenicity in mice","volume":"12","author":"Qin","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib93","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-022-01940-w","article-title":"Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants","volume":"19","author":"Liao","year":"2022","journal-title":"Virol. J."},{"key":"10.1016\/j.heliyon.2024.e34927_bib94","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.76.17.8769-8775.2002","article-title":"Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer","volume":"76","author":"Lewis","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e34927_bib96","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/COH.0000000000000056","article-title":"Adeno-associated virus delivery of broadly neutralizing antibodies","volume":"9","author":"Schnepp","year":"2014","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.heliyon.2024.e34927_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.2618","article-title":"Broad protection against influenza infection by vectored immunoprophylaxis in mice","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006299","article-title":"Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza","volume":"5","author":"Limberis","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e34927_bib99","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1089\/hum.2021.079","article-title":"Adeno-associated virus vector-mediated expression of antirespiratory syncytial virus antibody prevents infection in mouse airways","volume":"32","author":"Tycko","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib100","series-title":"Fields Virol","article-title":"Rhabdoviridae","author":"Lyles","year":"2013"},{"key":"10.1016\/j.heliyon.2024.e34927_bib101","first-page":"479","article-title":"Reverse genetics of Mononegavirales: how they work, new vaccines, and new cancer therapeutics","author":"Pfaller","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.heliyon.2024.e34927_bib102","doi-asserted-by":"crossref","DOI":"10.1002\/j.1460-2075.1994.tb06739.x","article-title":"Infectious rabies viruses from cloned cDNA","volume":"13","author":"Schnell","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.heliyon.2024.e34927_bib105","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14712598.2020.1787981","article-title":"A tool with many applications: vesicular stomatitis virus in research and medicine","volume":"20","author":"Munis","year":"2020","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06741-w","article-title":"Non-neutralizing antibodies elicited by recombinant Lassa\u2013Rabies vaccine are critical for protection against Lassa fever","volume":"9","author":"Abreu-Mota","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e34927_bib107","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1080\/21645515.2019.1649532","article-title":"Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens","volume":"15","author":"Fathi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e34927_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.heliyon.2024.e34927_bib109","article-title":"Optimization of single-dose VSV-based COVID-19 vaccination in hamsters","volume":"12","author":"O'Donnell","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104203","article-title":"Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera","volume":"82","author":"Espeseth","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib111","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1128\/JVI.72.6.4704-4711.1998","article-title":"Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge","volume":"72","author":"Roberts","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib112","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02308-14","article-title":"Rhabdovirus-based vaccine platforms against henipaviruses","volume":"89","author":"Kurup","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","article-title":"Rescue of measles viruses from cloned DNA","volume":"14","author":"Radecke","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.heliyon.2024.e34927_bib118","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.73.6.5001-5009.1999","article-title":"Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence","volume":"73","author":"Peeters","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/vim.2017.0143","article-title":"Measles vaccine","volume":"31","author":"Griffin","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11262-017-1486-3","article-title":"Vaccine platform recombinant measles virus","volume":"53","author":"M\u00fchlebach","year":"2017","journal-title":"Virus Gene."},{"key":"10.1016\/j.heliyon.2024.e34927_bib123","doi-asserted-by":"crossref","first-page":"9788","DOI":"10.1073\/pnas.0703584104","article-title":"Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens","volume":"104","author":"DiNapoli","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib124","author":"DiNapoli"},{"key":"10.1016\/j.heliyon.2024.e34927_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-42004-4","article-title":"Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in Guinea pigs","volume":"9","author":"Yoshida","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e34927_bib129","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.80.5.2267-2279.2006","article-title":"A single intranasal inoculation with a paramyxovirus-vectored vaccine protects Guinea pigs against a lethal-dose Ebola virus challenge","volume":"80","author":"Bukreyev","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib130","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.75.10.4594-4603.2001","article-title":"Recombinant bovine\/human parainfluenza virus type 3 (B\/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can Be used to achieve simultaneous mucosal immunization against RSV and HPIV3","volume":"75","author":"Schmidt","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib131","doi-asserted-by":"crossref","first-page":"11198","DOI":"10.1128\/JVI.78.20.11198-11207.2004","article-title":"Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in african green monkeys","volume":"78","author":"Tang","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib132","article-title":"Human parainfluenza virus type 3 expressing the respiratory syncytial virus pre-fusion F protein modified for virion packaging yields protective intranasal vaccine candidates","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e34927_bib133","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(04)16501-X","article-title":"Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS","volume":"363","author":"Bukreyev","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e34927_bib134","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109744118","article-title":"A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters","volume":"118","author":"Liu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2012.10.083","article-title":"Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development","volume":"31","author":"Kushnir","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.heliyon.2024.e34927_bib136","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib142","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/BC.2008.064","article-title":"The coming of age of virus-like particle vaccines","volume":"389","author":"Jennings","year":"2008","journal-title":"Biol. Chem."},{"key":"10.1016\/j.heliyon.2024.e34927_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/v15051109","article-title":"Virus-like particle vaccines and platforms for vaccine development","volume":"15","author":"Kheirvari","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib144","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins","year":"2013","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2024.e34927_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9080920","article-title":"Influenza virus-like particle (Vlp) vaccines expressing the sars-cov-2 s glycoprotein, s1, or s2 domains","volume":"9","author":"Chu","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2021.198305","article-title":"A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein","volume":"295","author":"Roy","year":"2021","journal-title":"Virus Res."},{"key":"10.1016\/j.heliyon.2024.e34927_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9020073","article-title":"Newcastle disease virus-like particles displaying prefusion-stabilized sars-cov-2 spikes elicit potent neutralizing responses","volume":"9","author":"Yang","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib164","doi-asserted-by":"crossref","DOI":"10.3390\/v15020392","article-title":"Respiratory viruses and virus-like particle vaccine development: how far have we advanced?","volume":"15","author":"Chu","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib165","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiy316","article-title":"Role of antibodies in protection against Ebola virus in nonhuman primates immunized with three vaccine platforms","author":"Warfield","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib166","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jir346","article-title":"Advances in virus-like particle vaccines for filoviruses","volume":"204","author":"Warfield","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib168","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-023-00754-3","article-title":"A recombinant virus-like particle vaccine against adenovirus-7 induces a potent humoral response","volume":"8","author":"Mazboudi","year":"2023","journal-title":"Npj Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib170","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/14760584.2019.1698952","article-title":"Ebola vaccine trials: progress in vaccine safety and immunogenicity","volume":"18","author":"Matz","year":"2019","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib173","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2016.1225637","article-title":"Ebola vaccines in clinical trial: the promising candidates","volume":"13","author":"Wang","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e34927_bib175","doi-asserted-by":"crossref","first-page":"10605","DOI":"10.1128\/JVI.00558-11","article-title":"Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses","volume":"85","author":"Blaney","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib176","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001275","article-title":"A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus","volume":"5","author":"Tsuda","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.heliyon.2024.e34927_bib177","doi-asserted-by":"crossref","DOI":"10.1038\/srep21674","article-title":"Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection","volume":"6","author":"Marzi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e34927_bib167","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2237038100","article-title":"Ebola virus-like particles protect from lethal Ebola virus infection","volume":"100","author":"Warfield","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2024.e34927_bib178","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines6020029","article-title":"Clinical advances in viral-vectored influenza vaccines","volume":"6","author":"Sebastian","year":"2018","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2022.01.011","article-title":"A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice","volume":"30","author":"Bliss","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.heliyon.2024.e34927_bib185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms8111745","article-title":"New technologies for influenza vaccines","volume":"8","author":"Rockman","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.heliyon.2024.e34927_bib187","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10071618","article-title":"Cross-protection induced by virus-like particles derived from the influenza B virus","volume":"10","author":"Kang","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib188","doi-asserted-by":"crossref","DOI":"10.3390\/v14020429","article-title":"Multiple neuraminidase containing influenza virus-like particle vaccines protect mice from avian and human influenza virus infection","volume":"14","author":"Kang","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.heliyon.2024.e34927_bib189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/vaccines7030119","article-title":"Viral vectors for the induction of broadly neutralizing antibodies against HIV","volume":"7","author":"Wilmschen","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib191","article-title":"Adenovirus vectors as HIV-1 vaccines: where are we? What next?","volume":"29","author":"Dsouza","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.heliyon.2024.e34927_bib196","doi-asserted-by":"crossref","DOI":"10.1038\/nrmicro2090","article-title":"The spike protein of SARS-CoV - a target for vaccine and therapeutic development","volume":"7","author":"Du","year":"2009","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib203","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9080881","article-title":"Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 and fully protects mice from lethal challenge","volume":"9","author":"King","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.heliyon.2024.e34927_bib206","article-title":"Protection from COVID-19 with a VSV-based vaccine expressing the spike and nucleocapsid proteins","volume":"13","author":"O'Donnell","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e34927_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.168173","article-title":"Highly attenuated poxvirus-based vaccines against emerging viral diseases","volume":"435","author":"Perdiguero","year":"2023","journal-title":"J. Mol. Biol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024109589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024109589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:58:30Z","timestamp":1784066310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024109589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":207,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024109589"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34927","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e34927"}}